Uninterrupted oral anticoagulant therapy in patients undergoing unplanned percutaneous coronary intervention

被引：0
|
作者：
Venetsanos, D. [1 ]
Skibniewski, M. [2 ]
Janzon, M. [2 ]
Lawesson, S. [2 ]
Henareh, L. [1 ]
Bohm, F. [1 ]
Andell, P. [1 ]
Karlson, L. [2 ]
Simonsson, M. [1 ]
Erlinge, D. [3 ]
Omerovic, E. [4 ]
Alfredsson, J. [2 ]
机构：
[1] Karolinska Univ Hosp, Stockholm, Sweden
[2] Linkoping Univ Hosp, Cardiol, Linkoping, Sweden
[3] Skane Univ Hosp, Lund, Sweden
[4] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2576 / 2576
页数：1
相关论文
共 50 条
  • [31] Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy
    Vidula, Mahesh K.
    McCarthy, Cian P.
    Butala, Neel M.
    Kennedy, Kevin F.
    Wasfy, Jason H.
    Yeh, Robert W.
    Secemsky, Eric A.
    [J]. PLOS ONE, 2018, 13 (10):
  • [32] Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment A meta-analysis
    Chen, Chao-Feng
    Chen, Bin
    Zhu, Jue
    Xu, Yi-Zhou
    [J]. HERZ, 2015, 40 (08) : 1070 - 1083
  • [33] Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatmentA meta-analysis
    Chao-Feng Chen
    Bin Chen
    Jue Zhu
    Yi-Zhou Xu
    [J]. Herz, 2015, 40 : 1070 - 1083
  • [34] Bleeding is a Major Cause of Early Readmission After Percutaneous Coronary Intervention Among Patients on Oral Anticoagulant Therapy
    Vidula, Mahesh K.
    McCarthy, Cian
    Secemsky, Eric A.
    Kennedy, Kevin F.
    Butala, Neel M.
    Wasfy, Jason H.
    Yeh, Robert W.
    [J]. CIRCULATION, 2017, 136
  • [35] After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
    Rubboli, Andrea
    Lisi, Matteo
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (04) : 499 - 500
  • [36] After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
    Andrea Rubboli
    Matteo Lisi
    [J]. Cardiovascular Drugs and Therapy, 2019, 33 : 499 - 500
  • [37] Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
    Dewilde, Willem J. M.
    Oirbans, Tom
    Verheugt, Freek W. A.
    Kelder, Johannes C.
    De Smet, Bart J. G. L.
    Herrman, Jean-Paul
    Adriaenssens, Tom
    Vrolix, Mathias
    Heestermans, Antonius A. C. M.
    Vis, Marije M.
    Tijsen, Jan G. P.
    van 't Hof, Arnoud W.
    ten Berg, Jurrien M.
    [J]. LANCET, 2013, 381 (9872): : 1107 - 1115
  • [38] Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise
    Gragnano, Felice
    Calabro, Paolo
    Cattano, Davide
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (04) : 424 - 426
  • [39] Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention - The need for consensus and a management guideline
    Lip, Gregory Y. H.
    Karpha, Manas
    [J]. CHEST, 2006, 130 (06) : 1823 - 1827
  • [40] Combined Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Navigating Between Scylla and Charybdis
    Doherty, John U.
    [J]. ANNALS OF INTERNAL MEDICINE, 2020, 172 (07) : 495 - 496
12345